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 Probiotics and dietary 
manipulations in calcium 
oxalate nephrolithiasis: two 
sides of the same coin? 
 Loris  Borghi 1 ,  Antonio  Nouvenne 1 and  Tiziana  Meschi 1  
 Growing evidence has assigned to oxalate a pivotal role in calcium 
nephrolithiasis pathophysiology. A better understanding of the 
mechanisms behind intestinal absorption and renal excretion has led to 
the identification of new treatments. Among these, diet and probiotics 
appear promising in terms of safety and rationale. However, the 
discrepancy between  in vitro and  in vivo results requires further studies 
to identify the right patient target, the correct dosage, and the real 
modification of natural and clinical history of nephrolithiasis. 
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 In recent decades, an advance in technol-
ogy has led to an improvement in the 
 effi  cacy of urological treatments for idio-
pathic calcium nephrolithiasis. From 
a pathophysiological point of view, 
in-depth studies — for example, those car-
ried out on Randall ’ s plaques and molecu-
lar aspects — have allowed better defi nition 
of the illness and currently weaken the 
hypothesis that nephrolithiasis is a simple 
combination of chemical – physical factors 
that induce crystallization. 1 Nevertheless, 
the prevalence of calcium oxalate nephro-
lithiasis is rising in industrialized coun-
tries, and we can still consider this disease 
an  ‘ orphan ’ of eff ective drugs. 
 This becomes crucial because the 
apparent role of oxalate in determining 
the risk and development of calcium 
nephrolithiasis seems to be increasing; 
according to some, it is more relevant 
than calcium itself. This is true both for 
 simple chemical – physical and stoichiomet-
ric events in the crystallization process, 
which cause small variations in the 
 concentrations of urinary oxalate to 
determine greater changes in calcium 
oxalate supersaturation values, and for 
our growing knowledge of other mecha-
nisms involved. For example, the renal 
reabsorption of oxalate is linked to other 
ions (sulfate, chloride, other anions) 
through a specifi c family of transporters, 
solute carrier family 26A (SLC26A); 2 in 
fact, patients with cystic fi brosis in which 
there is a defect in the chloride channel 
CFTR, which is co- regulated with some 
receptors of the SLC2A family, show 
hyperoxaluria and an increased  incidence 
of calcium oxalate nephrolithiasis. More-
over, oxalate itself seems to reduce renal 
blood fl ow and is responsible for micro-
vascular damage due to an insufficient 
crystal clearance; it has been suggested that 
this is one of the  possible mechanisms 
explaining the greater prevalence of neph-
rolithiasis in hypertensive subjects. In fact, 
it has been demonstrated that the admin-
istration of  ‘ vasodilators ’ such as enalapril 
or losartan in rats with ethylene glycol-
induced nephrolithiasis reduces tubu-
lointerstitial lesions. Finally, interactions of 
oxalate with renal epithelium could induce 
oxidative stress with apoptotic and regen-
erative stimu lus and greater crystal adhe-
sion capacity. 
 It is therefore clear how important and 
at the same time how complex the medical 
treatment of idiopathic calcium nephro-
lithiasis is. An interesting study by Lieske 
 et al. 3 (this issue) shows the diffi  culty of 
translating research on calcium oxalate 
nephrolithiasis from bench to bedside; 
assumptions based on excellent  in vitro 
studies have proved to be ineffi  cient in 
 in vivo experiments. 
 Must we, therefore, conclude that pro-
biotics are ineff ective in the treatment of 
calcium nephrolithiasis? Probably not. 
Th e problem is rather to identify in which 
patients they actually work. In fact, given 
the variable absorption of oxalate in the 
gastrointestinal tract (from 7 % to 72 % ), 
the amount of oxalate intake in the diet 
becomes crucial. It is not surprising that 
major proof of a fall in oxaluria following 
the use of probiotics derives from studies 
that analyzed patients with enteric hyper-
oxaluria 4 or aft er an oral load of oxalate; 5 
in contrast, results with mild hyperoxalu-
ria are not very satisfactory. 6 
 Many factors are involved in determin-
ing the amount of gastrointestinal oxalate 
absorption. We can identify at least four 
pivotal points: 1,2,7 (1) the amount of solu-
ble oxalate and / or its precursors that is 
naturally present in foods; (2) other foods 
or nutrients that can infl uence the absorp-
tion of oxalate because of competition or 
formation of non-absorbable complexes 
(for example, calcium, magnesium, lipids, 
fi ber); (3) intestinal fl ora and the pres-
ence of microorganisms capable of 
metabolizing oxalate; and (4) variations 
of pH and density of anion transporters 
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(SLC26A) along the gastrointestinal 
tract ( Figure 1 ). 
 Of these four elements, the fi rst three 
can hypothetically be easily modifi ed by 
dietary or pharmacological treatments. A 
variable amount of blood oxalate, between 
20 % and 45 % , comes from the diet (exog-
enous sources). However, because of the 
diffi  culty of dosing and the changes fol-
lowing food processing, most databases 
and nutritional soft ware show extremely 
discrepant food oxalate concentration 
values, and data are oft en lacking or unre-
liable. For this reason, in clinical practice, 
it seems inappropriate to recommend 
a simple elimination of food known to 
have high oxalate concentrations. In other 
words, to ban food rich in oxalate, such 
as chocolate, tea, rhubarb, spinach, beet-
root, parsley, okra, soybeans, yams, wheat 
bran, nuts, peanuts, and black pepper, 
seems insuffi  cient, as these foods are not 
usually consumed in high quantities or 
continuously over a long period of time. 
More over, an association with other 
foods, such as milk or dairy products rich 
in calcium, modifi es the bioavailability of 
oxalate as the amount of soluble oxalate 
available for absorption is reduced; also 
for this reason, the literature reports a 
wide percentage range of absorption 
(from 7 % to 72 % ). Furthermore, not 
much is known about the content in food 
of oxalate precursors such as  l -glycerate, 
hydroxypyruvate, glyoxylate, glycolate, 
and hydroxyproline. In particular, 
hydroxyproline could play an important 
role, as it is one of the main components 
of collagen, which in turn is one of the 
major proteins present in meat (more 
than 30 % in red meat). 
 Th e consumption of simple sugars may 
also increase the production and excre-
tion of oxalate. Although data from the 
literature are not homogeneous, it is 
known from epidemiological studies that 
a high consumption of fructose and 
sucrose is associated with an increased 
risk of calcium oxalate nephrolithiasis. 
On the other hand, fructose, thanks to a 
still unclear mechanism, is capable of 
increasing urinary oxalate; at the same 
time, carbo hydrates are among the main 
donors of carbon in the hepatic endog-
enous synthesis of glyoxylate and, there-
fore, of oxalate. 
 Another important point is the pres-
ence of microorganisms that use oxalate 
in their metabolism, such as  Oxalobacter 
formigenes . Th ese bacteria localize prefer-
entially in the colon. Significantly, an 
almost doubled colonization rate has been 
reported in normal subjects compared 
with nephrolithiatic subjects; colonization 
with  O. formigenes is associated with a 
70 % reduction of the risk of relapsing 
nephrolithiasis; and patients subjected to 
prolonged antibiotic therapy leading 
to a disequilibrium of the intestinal fl ora 
(for example, with cystic fi brosis) have 
a greater incidence of calcium oxalate 
nephrolithiasis. Besides  O. formigenes , 
numerous other strains have been tested 
(for example, lactobacilli and bifi dobacte-
ria); good results  in vitro have not always 
been confi rmed  in vivo . 
 The study by Lieske  et al. 3 proves 
the above-mentioned rationale; in fact, it 
confi rms that a normal-calcium diet with a 
controlled content of salt, lipids, proteins, 
and calories is effi  cient in reducing urinary 
oxalate, as we have already suggested. 8 – 10 
Various hypothetical mechanisms are 
responsible for the reduction of oxaluria 
through this type of diet. Firstly, an 
increased calcium intake as compared 
with a free-choice diet is possible, with a 
subsequently greater formation of non-
reabsorbable calcium oxalate complexes 
in the gastrointestinal tract; secondly, a 
reduced sodium chloride intake could 
reduce the intestinal absorption of oxalate 
and its excretion in the renal tubules 
through modulation of the SLC26A6 
channel, which stimulates the reuptake of 
chloride in the proximal tubule. Moreover, 
a reduction in salt could, in theory, lead to 
a reduction in calciuria as a result of com-
petition between the two cations in 
 tubular reabsorption with subsequent 
homeostatic regulation: an increase in the 
ionized plasma calcium, a subsequent 
decrease in parathyroid hormone and 
vitamin D, and thus a reduction in the 
intestinal reabsorption of calcium and a 
greater amount of calcium available in the 
intestinal lumen. Th is hypothesis is prob-
ably true in the case of hyper calciuria; 
Ileum
Oxalate absorption 1%–35%
Promoting factor:
• SCL26A density
Opposing factors:
• [Ca++]
• [Mg++]
• high pH
Stomach
Oxalate absorption 1%–10%
Promoting factors:
• pH < 2
• slow emptying time
Opposing factors:
• [Ca++]
• [Mg++]
• fast emptying time
Colon
Oxalate absorption 1–35%
Promoting factor:
• low pH
Opposing factor:
• degradation by
  Oxalobacter formigenes
Lipids
Oxalate
Calcium
Oxalobacter
formigenes
SLC26A
 Figure 1  |  Oxalate absorption in the gastrointestinal tract and the main factors involved. 
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in fact, it is not manifest in the data pre-
sented by Lieske  et al. , 3 possibly because 
the basal values of calciuria in the patients 
studied were relatively low. Moreover, the 
limited intake of lipids (15 % of the total 
calories) gives an increase of the amount 
of free calcium in the bowel. Finally, the 
reduced intake of animal protein trans-
lates into a minor availability of hydroxy-
proline, which, as already mentioned, is 
an important precursor of oxalate. 
 With regard to the apparent failure of 
the probiotic therapy tested by Lieske 
 et al. , 3 one can speculate that the subjects 
examined, having been in any case on a 
low-oxalate diet, were characterized by a 
low intestinal oxalate load and, therefore, 
subsequently reduced substrate for 
microorganisms. In fact, many studies 
that have found probiotic therapy eff ec-
tive in treating hyperoxaluria and, in 
gene ral, calcium nephrolithiasis exam-
ined patients with oxalate values greater 
than those in the current study or patients 
who were given an oral oxalate load. It is 
also possible that the probiotic dose was 
inadequate. 
 Ultimately, in calcium nephrolithiasis 
with hyperoxaluria treatment, along with 
the necessary dietary prescriptions —
 including adequate hydration; reduction 
in salt, proteins, lipids, and simple sugars; 
and correct intake of calcium, fruit, and 
vegetables — therapy with probiotics also 
plays a role, particularly in patients with 
enteric hyperoxaluria and / or high values 
of oxaluria. 
 In the future, dose-fi nding studies will 
be necessary, as well as a careful selection 
of the microorganism strains on the basis 
of metabolic characteristics, vitality, intes-
tinal colonization capacity, and eff ects of 
association with prebiotics (for example, 
inulin), in order to possibly test the effi  -
cacy in other types of nephrolithiasis, such 
as uric acid nephrolithiasis. 
 We look forward to seeing advances 
in technology and an improvement 
of knowledge in order to create, in the 
short term, true  ‘ functional foods ’ 
for nephrolithiasis that are useful in 
the prevention and treatment of this 
common disease. 
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 Potential benefits of alkali 
therapy to prevent GFR loss: 
time for a palatable  ‘ solution ’ 
for the management of CKD 
 Vaibhav  Sahni 1 ,  Robert M.  Rosa 1 and  Daniel  Batlle 1 
 There is increasing evidence that alkali therapy can retard progression of 
chronic kidney disease (CKD). We summarize recent studies and discuss a 
mechanism whereby alkali therapy may neutralize acid production 
associated with typical Western diets, which generate acid. We emphasize 
the rationale for using alkali therapy early in the course of CKD, even in the 
absence of overt metabolic acidosis, and we urge the pharmaceutical 
industry to develop palatable alkali- containing solutions. 
 Kidney International (2010)  78, 1065 – 1067.  doi: 10.1038/ki.2010.364 
 Traditionally, alkali therapy in chronic 
kidney disease (CKD) has been reserved 
for patients with overt metabolic acidosis. 
Th e reasoning has been that the primary 
purpose in treating metabolic acidosis 
associated with CKD is to prevent bone 
disease, improve the nutritional status, 
and prevent muscle wastage. 1 Th ese goals 
are themselves very good reasons to use 
more bicarbonate therapy in the CKD 
population, and the Kidney Disease Out-
comes Quality Initiative (K / DOQI) 
guidelines now have addressed this issue, 
though, in our opinion, not as forcefully 
as would be desirable. 2 In this Commen-
tary, we wish to address recent evidence 
that bicarbonate therapy may help pre-
vent the decline of glomerular fi ltration 
rate (GFR) over time. The question 
we would like to pose is: Should alkali 
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